How does ACE-031 (ACVR2B-Fc) work?
Soluble activin receptor IIB fused to immunoglobulin Fc. Acts as a decoy receptor that traps myostatin and other TGF-β superfamily ligands before they can activate native receptors on muscle cells, removing the brake on muscle growth. In plain terms, ACE-031 (ACVR2B-Fc) is a muscle-building drug that blocks the body's brake on muscle, shelved over safety. A soluble activin receptor IIB fused to Fc that traps myostatin and related TGF-β ligands. Acceleron developed it; Phase 2 dosing was halted in 2011 over vascular safety signals (program permanently discontinued 2013). Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Researchers studying myostatin pathway
- Educational reference, not for active use
- Followers of muscle-wasting drug development history
References
- ACE-031 (soluble activin receptor IIB) increases muscle mass, Phase 1 in postmenopausal women — Attie KM et al., Muscle Nerve, 2013
- Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial — Campbell C, McMillan HJ, Mah JK, et al., Muscle & Nerve, 2017
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ACE-031 (ACVR2B-Fc)
Last updated 2026-06-06.